source
- Lilly's 14th acquisition of the year is a little-known blood cancer biotechEli Lilly has been on a shopping spree this year thanks to its GLP-1-driven revenue, and its 14th acquisition of 2026 is in cancer, the domain of expertise for the pharma's head ...Endpoints · 56m ago↗ source
- ObesityWeek 2026: Wave outlines case for body composition–based trial designAcross three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw s…BioSpace · 58m ago↗ source
- STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and moreDuring July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous year